 |
|
Enhancing the effects of the drug used to treat chronic myeloid leukemia
April 14, 2009Individuals with chronic myeloid leukemia (CML) are first treated with a drug known as imatinib mesylate. Although very effective, as the disease progresses it often becomes resistant to the drug. However, a team of researchers, at the University of Leicester, United Kingdom, and Thomas Jefferson University, Philadelphia, has identified a class of drugs that might enhance the therapeutic effects of imatinib mesylate and other drugs that target the same molecule.
The team, led by Paolo Salomoni and Bruno Calabretta, observed that for several different CML cell lines and primary cells, although imatinib mesylate killed the majority of cells, a marked proportion underwent a process known as autophagy.
Consistent with studies indicating that the induction of autophagy can provide a mechanism of cellular survival, suppression of autophagy using either drugs or RNA interference enhanced imatinib mesylate-induced death of CML cell lines, primary CML cells, and CML stem cells. The authors therefore suggest that inhibitors of autophagy might be used with imatinib mesylate or other drugs that target the same molecule to enhance their therapeutic benefits.
View the PDF of this article at: https://www.the-jci.org/article.php?id=35660
Journal of Clinical Investigation
View the PDF of this article at: https://www.the-jci.org/article.php?id=35660
Journal of Clinical Investigation
Chronic Myeloid Leukemia Current Events and Chronic Myeloid Leukemia News RSSFDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
Drug could provide first treatment for scleroderma
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.
Finding key to cancer drug Gleevec's limitations
University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.
Novel epigenetic markers of melanoma may herald new treatments for patients
Melanoma is the most serious form of skin cancer, diagnosed in more than 50,000 new patients in the United States annually. While the rate of incidences continues to rise, survival rate has not improved and the race is on to find the genetic and cellular changes driving melanoma and to devise new means of detection and treatment.
A lethal cancer knocked down by one-two drug punch
In the battle against cancer, allies can come from unexpected sources. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market.
Stem cell protein offers a new cancer target
A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.
Therapeutic effect of imatinib improved with addition of chloroquine
The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation.
Scientists uncover indicator that warns leukemia is progressing to more dangerous form
Scientists at the Moores Cancer Center at the University of California, San Diego, Stanford University School of Medicine and other centers have identified a mechanism by which a chronic form of leukemia can progress into a deadlier stage of the disease.
OHSU Knight Cancer Institute researcher: study may result in more targeted drugs for GIST
According to Oregon Health & Science University Knight Cancer Institute researchers, there is strong evidence that patients can have varying clinical responses to medications depending on the specific makeup of their cancer.
New research to help dogs with cancer may benefit people
A new study jointly conducted by Oregon State University College of Veterinary Medicine and the Oregon Health & Science University Cancer Institute may one day help not only our canine friends with cancer, but also people with the human form of the disease.
More Chronic Myeloid Leukemia Current Events and Chronic Myeloid Leukemia News Articles
 |
Chronic Myeloid Leukemia by Jorge Cortes (Editor), Michael Deininger (Editor) Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve patient care. Providing critical insight and exploration of models that will enhance the cancer community at large, this source: stands as the only source to focus on post-Gleevec... |
 |
Can We Cure the Common Leukemias? |
|
Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.(CASE REPORTS): An article from: Journal of Drugs in Dermatology by E. Ladoyanni (Author), R. Nambi (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on March 1, 2005. The length of the article is 951 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.(CASE REPORTS) Author: E. Ladoyanni Publication: Journal of Drugs in Dermatology (Refereed) Date: March 1, 2005 Publisher: Journal of Drugs in Dermatology, Inc. Volume: 4 Issue: 2 Page: 221(2) Distributed by Thomson... | |
 |
Chronic Myeloid Leukemia: Biology and Treatment by Angelo M Carella (Editor), George Q Daley (Editor), Connie J. Eaves (Editor), John M Goldman (Editor), Hehlmann Rudiger (Editor) (Martin Dunitz) Ospedale 'Case Sollievo della Sofferenza'-IRCCS, San Giovanni Rotondo, Italy. Reflects changes in the field of chronic myeloid leukemia, during the past decade. Topics discusses include the molecular and cellular biology of CML, conventional chemotherapy and interferon therapy, and recent developments in allografting and autografting. |
![Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated ... Toxicology and Environmental Mutagenesis]](http://ecx.images-amazon.com/images/I/51VRJGWFK9L._SL160_.jpg) |
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated ... Toxicology and Environmental Mutagenesis] by I. Majsterek (Author), T. Sliwinski (Author), T. Poplawski (Author), D Pytel (Author) This digital document is a journal article from Mut.Res.-Genetic Toxicology and Environmental Mutagenesis, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Imatinib mesylate (STI571), a specific inhibitor of BCR/ABL tyrosine kinase, exhibits potent antileukemic effects in the treatment of chronic myelogenous leukemia (CML). However, the precise mechanism by which inhibition of BCR/ABL activity results in pharmacological responses remains unknown. BCR/ABL-positive human K562 CML cells resistant to doxorubicin (K562DoxR) and their sensitive counterparts (K562DoxS) were used to determine the mechanism by which the STI571 inhibitor may... |
|
Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia): An article from: Internal Medicine News by Sharon Worcester (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on July 15, 2002. The length of the article is 497 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Gleevec beats interferon for initial CML therapy. (Open-Label Phase III Trial).(chronic myeloid leukemia) Author: Sharon Worcester Publication: Internal Medicine News (Magazine/Journal) Date: July 15, 2002 Publisher: International Medical News Group Volume: 35 Issue: 14 Page: 25(1) Article Type: Product/Service Evaluation Distributed by... | |
|
The Role of the Philadelphia Translocation in Chronic Myeloid Leukemia by Adrianus Henricus Maria Geurts Van KESSEL (Author) Primarily in English. | |
|
Imatinib beats interferon for first-line initial CML therapy. (Chronic Myeloid Leukemia).(chronic myeloid leukemia): An article from: Internal Medicine News by Mitchel L. Zoler (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on February 1, 2003. The length of the article is 842 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Imatinib beats interferon for first-line initial CML therapy. (Chronic Myeloid Leukemia).(chronic myeloid leukemia) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: February 1, 2003 Publisher: International Medical News Group Volume: 36 Issue: 3 Page: 45(1) Article Type: Product/Service... | |
|
Betanin a betacyanin pigment purified from fruits of Opuntia ficus-indica induces apoptosis in human chronic myeloid leukemia Cell line-K562.: An article ... Journal of Phytotherapy & Phytopharmacology by Devalraju Sreekanth (Author), M.K. Arunasree (Author), Karnati R. Roy (Author), T. Chandramohan Reddy (Author), Gorla V. Reddy (Author), Pallu Reddanna (Author) This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Thomson Gale on November 1, 2007. The length of the article is 4746 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Betanin a betacyanin pigment purified from fruits of Opuntia ficus-indica induces apoptosis in human chronic myeloid leukemia Cell line-K562. Author: Devalraju Sreekanth Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Magazine/Journal) Date: November 1, 2007 Publisher: Thomson... | |
|
Oral agent shows promise for chronic myeloid leukemia.(Hematology): An article from: Internal Medicine News by International Medical News Group (Publisher) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2005. The length of the article is 424 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Oral agent shows promise for chronic myeloid leukemia.(Hematology) Publication: Internal Medicine News (Magazine/Journal) Date: January 15, 2005 Publisher: International Medical News Group Volume: 38 Issue: 2 Page: 40(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |